ArticleChemical science2020
Gd(iii)-Pt(iv) theranostic contrast agents for tandem MR imaging and chemotherapy.
Article in Chemical science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Beyond radiotheranostics: how imaging modality defines theranostics.European radiology experimental · 2026Review
- The impact of gadolinium doping on physicochemical properties and neuroprotective activity of polyacrylic acid conjugated cerium oxide nanoparticles - in vitro study of potential theranostics for neurodegenerative diseases.Pharmacological reports : PR · 2026Article
- A Triple Threat Against Ovarian Cancer: Os(II)-Pt(IV)-Ceritinib Conjugates for Photodynamic Therapy, Chemotherapy, and Immunogenic Cell Death Induction.Angewandte Chemie (International ed. in English) · 2025Article
- MR Imaging Reveals Dynamic Aggregation of Multivalent Glycoconjugates in Aqueous Solution.Inorganic chemistry · 2024Article
- Recent Advances on Pt-Based Compounds for Theranostic Applications.Molecules (Basel, Switzerland) · 2024Review
- Article
- Promising heterometallic compounds as anticancer agents: Recent studies in vivo.Current opinion in chemical biology · 2023Review
- Lanthanide porphyrinoids as molecular theranostics.Chemical Society reviews · 2022Review
- Challenges and opportunities in the development of metal-based anticancer theranostic agents.Bioscience reports · 2022Review
- Towards Imaging Pt Chemoresistance Using Gd(III)-Pt(II) Theranostic MR Contrast Agents.ChemMedChem · 2021Article
- Defining the conditions for the development of the emerging class of FeChemical science · 2021Article
- Cell-permeable lanthanide-platinum(IV) anti-cancer prodrugs.Dalton transactions (Cambridge, England : 2003) · 2021Article
- Smart magnetic resonance imaging-based theranostics for cancer.Theranostics · 2021Review
- Structure-guided discovery of a luminescent theranostic toolkit for living cancer cells and the imaging behavior effect.Chemical science · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pt(iv) prodrugs have emerged as versatile therapeutics for addressing issues regarding off-target toxicity and the chemoresistance of classic Pt(ii) drugs such as cisplatin and carboplatin. There is significant potential for Pt(iv) complexes to be used as theranostic agents, yet there are currently no reported examples of Gd(iii)-Pt(iv) agents for simultaneous MR imaging and chemotherapy. Here we report the synthesis, characterization, and
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.